Synapse - Works

Results (4640)

Precision management of a patient with dihydropyrimidine dehydrogenase deficiency and liver-predominant metastatic rectal cancer using hepatic arterial floxuridine

Journal Article

Lumish, M.; Thackray, J.; Do, R. K. G.; Caudle, K. E.; Amstutz, U.; Schwab, M.; Diasio, R. B.; Jarnagin, W. R.; Cercek, A.
JCO Precision Oncology (2023)

Fulltext@MSK | Save

Acupuncture vs massage for pain in patients living with advanced cancer: The IMPACT randomized clinical trial

Journal Article

Epstein, A. S.; Liou, K. T.; Romero, S. A. D.; Baser, R. E.; Wong, G.; Xiao, H.; Mo, Z. L.; Walker, D.; MacLeod, J.; Li, Q.; more...
JAMA Network Open (2023)

Fulltext@MSK | Save

Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress)

Meeting Abstract

Fritsch, R.; Andre, T.; Bekaii-Saab, T.; Cercek, A.; Nakamura, Y.; Raghav, K.; Siena, S.; Strickler, J.; Van Cutsem, E.; Adelberg, D.; more...
Swiss Medical Weekly (2023)

Fulltext@MSK | Save

Outcomes of stereotactic radiosurgery for colorectal cancer brain metastases

Meeting Abstract

Gui, C.; Mueller, K. D.; Eichholz, J. E.; Walch, H.; Khatri, I.; del Balzo, L.; Kemeny, N. E.; Imber, B. S.; Schultz, N.; Foote, M. B.; more...
Radiotherapy and Oncology (2023)

Fulltext@MSK | Save

Adverse event profiles and time to onset and resolution with tremelimumab ( T) plus durvalumab (D) in patients with unresectable hepatocellular carcinoma (uHCC) in the phase 3 HIMALAYA trial

Meeting Abstract

De Toni, E. M.; Sangro, B.; Chan, S. L.; Kudo, M.; Kelley, R. K.; K, K. Y.; Rimassa, L.; Varela, M.; Dayyani, F.; Makowsky, M.; more...
Oncology Research and Treatment (2023)

Fulltext@MSK | Save

Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress)

Meeting Abstract

Heinemann, V.; Bekaii-Saab, T.; Van Cutsem, E.; Tabernero, J.; Siena, S.; Yoshino, T.; Nakamura, Y.; Raghav, K.; Cercek, A.; Adelberg, D.; more...
Oncology Research and Treatment (2023)

Fulltext@MSK | Save

Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649

Meeting Abstract

Moehler, M.; Janjigian, Y. Y.; Shitara, K.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A.; more...
Oncology Research and Treatment (2023)

Fulltext@MSK | Save

Zolbetuximab + CAPOX in 1L Claudin-18.2+(CLDN18.2+)/HER2-locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW

Meeting Abstract

Lordick, F.; Xu, R. H.; Shitara, K.; Ajani, J. A.; Bang, Y. J.; Enzinger, P.; Ilson, D.; Van Cutsem, E.; Plazas, J. G.; Huang, J.; more...
Oncology Research and Treatment (2023)

Fulltext@MSK | Save

Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC)

Meeting Abstract

Galle, P. R.; Crysler, O.; Yarchoan, M.; Furuse, J.; Sukeepaisarnjaroen, W.; Thinh, N. T.; Masi, G.; Lim, H. Y.; Varela, M.; Gupta, C.; more...
Oncology Research and Treatment (2023)

Fulltext@MSK | Save

Zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (Pts) with claudin-18.2+(CLDN18.2+) / HER2-locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study

Meeting Abstract

Lordick, F.; Shitara, K.; Bang, Y. J.; Enzinger, P.; Ilson, D.; Shah, M. A.; Van Cutsem, E.; Xu, R. H.; Aprile, G.; Xu, J.; more...
Oncology Research and Treatment (2023)

Fulltext@MSK | Save